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ABSTRACT  
Background: We examined the diversity in paediatric vision and hearing screening 
programmes in Europe.      
Methods: Themes relevant for comparison of screening programmes were derived from 
literature and used to compile three questionnaires on vision, hearing and public-health 
screening. Tests used, professions involved, age and frequency of testing seem to influence 
sensitivity, specificity and costs most. Questionnaires were sent to ophthalmologists, 
orthoptists, otolaryngologists and audiologists involved in paediatric screening in all EU full-
member, candidate and associate states. Answers were cross-checked.  
Results: Thirty-nine countries participated; 35 have a vision screening programme, 33 a 
nation-wide neonatal hearing screening programme. Visual acuity (VA) is measured in 35 
countries, in 71% more than once. First measurement of VA varies from three to seven years 
of age, but is usually before the age of five. At age three and four picture charts, including Lea 
Hyvarinen are used most, in children over four Tumbling-E and Snellen. As first hearing 
screening test otoacoustic emission (OAE) is used most in healthy neonates, and auditory 
brainstem response (ABR) in premature newborns. The majority of hearing testing 
programmes are staged; children are referred after one to four abnormal tests. Vision 
screening is performed mostly by paediatricians, ophthalmologists or nurses. Funding is 
mostly by health insurance or state. Coverage was reported as >95% in half of countries, but 
reporting was often not first-hand. 
Conclusion: Largest differences were found in VA charts used (12), professions involved in 
vision screening (10), number of hearing screening tests before referral (1-4) and funding 
sources (8).  
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INTRODUCTION 
The sensory functions of a child play a key role in intellectual and social development during 
early childhood. Vision or hearing impairment therefore affects both personal and societal 
health of children. There is robust evidence that earlier detection of a visual or hearing deficit 
results in an improved outcome.1-4 Therefore, vision and hearing screening programmes have 
been introduced world-wide. Although the programmes are based on the same general 
principles, they still vary both within and across EU countries, regarding tests used, age of 
testing, frequency of testing, professions involved in screening, referral procedure, funding 
and coverage. These differences between screening programmes can result in health 
inequities. No screening or screening with little population coverage can result in delayed 
provision of the correct treatment and increased disease burden. Too abundant screening can 
result in inappropriate interventions and increased costs for health care systems.  
 
Vision screening and subsequent treatment has reduced the occurrence of insufficiently 
detected and treated amblyopia.5 In the Netherlands, the age that amblyopia is detected is 
nowadays more than two years earlier than in the seventies.6 Early screening for hearing 
impairment has led to early intervention and improved outcome.2,7 Early detection of hearing 
disorders and timely intervention such as cochlear implantation or hearing aid  largely 
prevents delayed language development,1 which also results in improved general 
developmental outcome at 3 to 5 years of age.3 
 
In spite of the increased consciousness world-wide that vision and hearing screening is 
effective, there are differences in implementation between countries. Neugebauer et al. did a 
survey of existing vision screening programmes in 190 countries via their ministries of health 
and found that screening was often state funded, visual acuity (VA) was always tested and 
within the EU screening was predominantly voluntary.8 Matta and Silbert assessed differences 
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in paediatric vision screening programmes through an e-mail survey to members of the 
International Orthoptic Association (IOA).  Ninety-eight percent of their 18 responsive 
representatives indicated that a vision screening programme was in place in their country; in 
44% this was a national programme. Screening was performed by a wide range of 
professionals.9   
Bubbico et al. reported an overview of implemented universal new-born hearing screening 
(UNHS) programmes in 24 European countries dating from the period 2004-2006. In several 
countries UNHS programmes were successfully introduced reaching more than 95% of all 
neonates, but in many other countries programmes were recently introduced or were only 
partially functioning.10 Reports on experiences with national neonatal hearing screening 
programmes concern issues on implementation, test procedures, type of tests, coverage, 
detected cases of hearing loss and costs.11-19   
 
The cost-effectiveness of screening programmes has been the subject of several reports. In a 
report by Carlton et al.,20 following the Health Technology Assessment (HTA) report by 
Snowdon and Stewart-Brown,21 the cost-effectiveness of vision screening up to the age of 4-5 
years was re-examined. They concluded that, based on the accepted value of a Quality-
adjusted life year (QALY), the cost-effectiveness of screening for amblyopia depends on the 
long-term utility effects of unilateral vision loss  and that there is currently no sustainable 
evidence of utility loss that would render any form of screening  likely to be cost-effective.20 
Keren et al. concluded that universal new-born hearing screening (UNHS) in general has the 
potential for long-term cost savings compared with selective hearing screening and no 
screening.22 Burke et al found that the cost-effectiveness of hearing screening depended 
mainly on the cost of the screening intervention per patient and on the prevalence of hearing 
loss in the population.23  
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The purpose of this study was to make an inventory of population-based vision and hearing 
screening programmes for children in Europe. It is known that differences exist, but to what 
extent is unknown. It is necessary to gain more insight into these differences.  This problem is 
in particular relevant for EU countries that currently have no screening programme in place: 
for new EU member states that want to implement vision and hearing screening, there is 
uncertainty about which screening protocol to adapt. If large differences are found in 
population-wide vision and hearing screening in children in all EU countries, further study on 
the relative costs and effectiveness of the different approaches to screening is necessary. 
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METHODS 
Items relevant for comparison of screening programmes were derived from literature, in 
particular from five major cost-effectiveness analyses.20, 21,23-25 The following main domains 
were used to formulate vision (Q1) and hearing (Q2) screening questionnaires: 
- Type of tests, like visual acuity chart or hearing screening device (OAE, aABR) used 
- Professions involved in screening, like nurses, orthoptists or doctors 
- Funding, for example by state or health insurance 
- Coverage, percentage of screened children 
  
Questions were formulated in a focus group and asked in a multiple-choice format with room 
for extra comments and multiple answers (Q1, Q2). All forms of screening for vision or 
hearing problems were included (e.g. inspection of the eyes was also counted as form of 
vision screening). To get a broader perspective of screening systems a short public-health 
questionnaire (Q3) was developed through extrapolation of the vision and hearing 
questionnaires. This very concise public-health questionnaire was only intended to provide 
background information on screening and screening systems in all countries.  
 
In all EU full member states (28), candidate states (5), potential candidate state Albania and 
associated states Israel, Moldova, Norway and Switzerland a paediatric ophthalmologist, 
orthoptist, otolaryngologist, audiologist and screening professional were approached to fill out 
the questionnaires regarding screening in their own country. These representatives were 
selected based on their involvement in paediatric vision and hearing screening. Existing 
connections were used to find the most appropriate persons to fill out the questionnaires. 
Where a representative could not be identified, new connections were asked to recommend 
representatives in neighbouring countries or colleagues involved in vision or hearing 
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screening in their own country. Public-health representatives were found by approaching 
Ministries of health and via recommendation of the vision and hearing representatives.  
 
Firstly questions about screening tests, age and frequency of screening were included in our 
questionnaire. Different tests can be used to screen for one disorder, but screening 
programmes can also focus on more than one disorder. Two-stage or multiple-stage testing 
improves the specificity of the screening, but makes the screening more expensive. The 
higher specificity however can reduce costs in diagnostics during follow-up.23,26  
 
Secondly questions about the choice of professions involved in screening were included 
because this influences the quality and costs of screening. Screening tests with a higher 
sensitivity and specificity might require higher educated personnel. This will lead to an 
increase in costs of screening due to longer education and higher salary costs. This increase in 
costs should be balanced with the increase in sensitivity and specificity.  
 
Thirdly, funding is an important issue in screening. Funding can be provided by the state, 
regions, municipalities, Health insurances, parents and/or charity.   the choice of funding 
agencies will influence the equity of screening, competitiveness, costs, coverage and cost-
effectiveness.    
Finally questions about coverage were included because the participation frequency of a 
screening programme is crucial for its effectiveness, and to make screening worthwhile from 
a population point of view. Low coverage can lead to delayed provision of the correct 
treatment and increased disease burden. If screening is free of charge or obligatory, coverage 
will be higher. Acceptable participation frequencies can be reached by incorporating the 
screening into an already existing system with a high participation rate, e.g. vaccination 
programmes or school start.  
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Questionnaires were distributed via e-mail from December 2013 until April 2014. Clinicians 
involved in population based screening were sought and their answers were cross-checked 
with the answers given by the general screening professionals. In case of ambiguities the 
questionnaires were returned to both the clinician and the screening professional and they 
were asked to contact each other and send us the agreed corrections. Overviews of the 
questionnaire answers  were made and these were circulated three times to all representatives. 
All representatives were asked to review and correct any errors in the overviews for their own 
country and for neighbouring countries. The overviews were also presented to and checked by 
external experts, who areinvolved first-hand in vision and hearing screening.   
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RESULTS 
In all 39 countries (including 2 separate regions in Belgium), representatives were found. 
Vision representatives were found in 36, hearing representatives in 38 and public-health 
representatives in 23 countries (Table 1).  
Table 1. Eligible countries (EU status: A =  associated state, C =  Candidate, M = full member, P.C. =  
potential candidate).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Country EU status Vision Hearing Public 
Albania P.C. - + + 
Austria  M.  + + - 
Belgium Flanders M.  + + + 
Belgium Wallonia M.  + + - 
Bulgaria  M.  + + + 
Croatia  M.  + + + 
Cyprus  M.  + + - 
Czech Republic  M.  + + + 
Denmark  M.  + + - 
Estonia  M.  + + - 
Finland  M.  + + + 
France  M.  + + + 
Germany  M.  + + + 
Greece  M.  + + + 
Hungary  M.  + + + 
Iceland C. + + + 
Ireland  M.  + + - 
Israel A. + + + 
Italy  M.  + + - 
Latvia  M.  + + - 
Lithuania  M.  + + - 
Luxembourg  M.  + + - 
Macedonia C. - - + 
Malta M.  + + + 
Moldova A. - + - 
Montenegro C. + + + 
Netherlands M.  + + + 
Norway A. + + - 
Poland M. + + - 
Portugal  M.  + + + 
Romania  M.  + + - 
Serbia C. + + + 
Slovakia  M.  + + - 
Slovenia  M. + + + 
Spain M. + + + 
Sweden  M. + + + 
Switzerland A. + + - 
Turkey C. + + + 
United Kingdom  M.  + + + 
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Vision 
Information on vision screening programmes was obtained from 36 countries including two 
regions in Belgium (Flanders and Wallonia). No information could be obtained from Albania, 
Macedonia and Moldova. Thirty-five countries have a vision screening programme in place. 
In Belgium, Bulgaria, Estonia, France, Romania, Spain and Switzerland this is a regional 
programme. In several countries with a national vision screening programme in place, 
regional differences in screening protocols do exist.  
 
Tests infant and preverbal screening 
Infant screening (age 0-4 months) included inspection, fixation, red reflex testing, Hirschberg 
test, Bruckner test, Cover test, pupillary reflexes and motility. Most countries perform a 
combination of two or more of these tests. In Bulgaria, Greece and Poland no screening is 
performed at this age. In Germany only inspection of the eyes is performed. In Ireland, 
Montenegro and Spain inspection of the eyes is combined with red reflex testing. In Cyprus, 
Italy, Lithuania and Malta only red reflex testing is done. In Latvia this is combined with 
motility testing. Preverbal screening (age 6-30 months) includes the same tests. At this age 
screening is not performed in eight countries. In most other countries a combination of two or 
more tests is performed.  
 
Visual acuity measurements 
In all countries visual acuity (VA) is tested, but the age of the first measurement varies 
between three and seven years of age. In a third of countries VA is tested once, one third 
twice and in one third more than two times. Thus in most countries VA measurements are 
repeated at an older age. In children age four years and younger the most common used VA 
charts are picture charts and the Lea Hyvarinen chart, above four years Tumbling E and 
Snellen are most often used.  
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Personnel and referral 
Screening is mostly performed by paediatricians, ophthalmologist and/or nurses. In all 
countries children are referred to the ophthalmologist for further examination, except for 
Latvia, where children are referred to the General Practitioner (GP), the UK where children 
may also be referred to joint orthoptic and optometry clinics or optometrists, Malta where 
children are referred to either the orthoptist or optometrist and the Netherlands where children 
are mostly referred via the GP to an orthoptist or ophthalmologist, but sometimes directly to 
an orthoptist, ophthalmologist, optometrist or optician. 
 
Funding 
In most countries vision screening is free of charge for parents, except for the Czech 
Republic, Malta, Switzerland and Turkey. Funding is in 33% (partially) provided by the 
Health Insurance and in 53% (partially) by the State. Parents and charity pay (part of the) 
screening in the Czech Republic, Latvia, Romania, Slovakia, Spain and Turkey. 
 
Coverage 
Coverage varied from just starting (Estonia, Portugal, Turkey) to  more than 95% in Austria, 
Czech Republic, Denmark, Finland, Flanders, Germany, Hungary, Iceland, Luxembourg, the 
Netherlands, Norway, Serbia, Slovenia, Sweden and parts of the UK. Coverage of different 
testing moments varied within countries: the number of children screened varied, dependent 
on the age that the screening test was carried out. The highest coverage percentage was 
regarded as coverage for each particular country.  
 
Data is presented in more detail in table 2 and Map 1. 
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Table 2. Vision screening programmes in 36 European countries. Scope =  scope of vision 
screening programme (nat =  nation-wide, loc =  local), Personnel: (ophth =  ophthalmologist, 
ped = paediatrician, school =  school physician, YHC = youth health care physician, orth =  
orthoptist, optom = optometrist, GP = general practitioner, optic =  optician, assist =  
practice assistant), Pres. =  preschool screening(screening before school age, school age 
varies across countries), Chart and age =  visual acuity chart and age of testing (Pict =  
Picture chart, Lea =  Lea Hyvarinen Chart (picture) C = Landolt C, E = Tumbling E, KM = 
Konstantin Moutakis, Sher =  Sheridan Gardiner, Snel =  Snellen), Auto. =  autorefraction/ 
photorefraction, Also =  testing of stereopsis and/or colour vision, Funding = (Insur =  health 
insurance, Munic =  Municipalities, Par =  parents), Cov. =  Coverage.  
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 Country Scope Personnel 0-4mo 
6-
30mo Pres. Chart and age Auto. Also Funding 
Cov. 
(%) 
Austria nat Ophth, ped, 
school + + + Lea 3; 4; 5; 6 - stereo 
insur, 
state >95 
Belgium (Fl) 
 
YHC, nurse + + + Pict 3½, HOTV 4½ + both region >95 
Belgium (W) nat Orth, ped, other + + + Snel 3½; 6 + - region >40 
Bulgaria loc GP - + - Pict, E 7 - colour insur   
Croatia nat Ophth, ped, 
school + + + Pict, Lea 4, E 6; 6½ - - 
insur, 
state >90 
Cyprus nat School + - - Snel 6½; 7 - - state >80 
Czech rep nat 
Ophth, orth, 
ped, YHC, 
optom, other 
+ + + 
Pict; Lea 3, E 5, Snel 7; 9; 11; 13; 
15  Loc. colour 
insur, par 
region >95 
Denmark nat Nurse, school, GP + + + Pict 3; 4; 5; 6  - - region >95 
Estonia loc Ophth, ped   + + + Lea 3, Lea; Snellen 6 - - insur start 
Finland nat Nurse, school, GP   + + + Lea 3; 4; 5½ - - 
state, 
munic >95 
France loc Orth, ped, 
nurse, school + + + Pict 4 - - 
insur, 
region >80 
Germany nat Ped + + + Lea; HOTV 3 - - insur >95 
Greece nat Ophth - - + Snel 5½ - both state >60 
Hungary nat Ped, nurse, 
school + + + Pict 6 Loc. both 
insur, 
state >95 
Iceland nat Ped, nurse  + + + Lea; HOTV 4, HOTV; Snel 6 - stereo state >95 
Ireland nat School + + - Snel 5½ - - state >80 
Israel nat Ped, nurse + + + Pict 3; 6 - - state >80 
Italy nat Ped + - + Snel (3); 6 - - region >80 
Latvia nat Ophth, ped + + + Cardiff 1, Pict; E 3, E; numbers 6½ - stereo state, par >60 
Lithuania nat Ophth, ped + + + Pict; E; Snel 6; 6½; 7 + - state   
Luxembourg nat Orth, ped, 
nurse  
+ + + Pict; E 3½, 4½, 5½, 6½ + both insur, 
state >95 
Malta nat Orth, nurse, 
optom, school + + - Snel 3, Sher 5½ - stereo state >80 
Montenegro nat Ped, nurse + + + Snel 5½ - - state   
Netherlands nat YHC, nurse + + + Pict 3, Lea; C 4 - - munic >95 
Norway nat Nurse, GP, 
school + + + Lea 4, Sher 6 - - munic >95 
Poland nat Ped, GP - + + Pict 4, Snel 6 - - state >80 
Portugal nat GP + - + Sher 4, E 5; E; C 5½; 6 - - state start 
Romania loc Ophth + - + Pict 3, Snel 4; 5 Loc. - state, 
charity >80 
Serbia nat Ophth, ped + + + Snel 6½ - both state >95 
Slovakia nat Ophth, orth, ped  + + + Pict 3, Lea; E; C; Snel, 5; 6 - both par, insur >90 
Slovenia nat Ped, school + + + Pict 3; 5 Snel 6; 7 - - insur >95 
Spain loc Ped, ophth, 
optom + - + Pict 4, Snel 4½; 5 - stereo par, state   
Sweden nat Nurse + - - HOTV 4, KM 6 - - region >95 
Switzerland loc 
Ophth, orth, 
ped, nurse, 
optic, school, 
GP 
+ + + Pict 4, Lea; E 4½; 5, 5½ - stereo insur >80 
Turkey start Ophth + + - E 5 - - par start 
UK nat Orth, nurse, 
assist + - - Sonksen; Keeler 4; 5 - - region >95 
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Hearing 
Information on neonatal hearing screening (NHS) programmes was obtained from 38 
countries including two regions: Flanders and Wallonia in Belgium. No information could be 
obtained from Macedonia. 
Nation-wide universal NHS programmes are present in 33 out of 38 countries. Malta has a 
nation-wide selective screening programme only for infants from neonatal and paediatric IC 
units. In Bulgaria, Moldova and Serbia local selective screening programmes for risk groups 
(premature new-borns) exist. Albania had for a few years a pilot nation-wide universal 
screening programme, which was discontinued due to lack of funds. 
 
Tests 
The most widely used audiometric test is otoacoustic emission (OAE). Flanders has used 
automated auditory brainstem response (aABR) in all neonates, but in 2013 measurement of 
aABR plus auditory steady state responses (ASSR) were introduced. Some regions in 
Denmark, Estonia, France, Germany, Spain and Sweden use aABR, OAE or both in the same 
infant as first test in well babies. In nearly all programmes both ears are tested. Exceptions are 
Finland and Switzerland where one or two ears are tested depending on the institution or the 
presence of risk factors. Testing is not staged in five countries, two-staged in 13 countries, 
three-staged in 19 countries and 4-staged in one country. aABR is used as final stage in the 
majority of countries. In risk groups such as premature new-borns, most programmes use 
aABR or a combination of OAE and aABR, but in eight countries OAE only is used. In 
Wallonia (Belgium) all premature infants undergo full ABR.  
 A hearing test in pre-school or early school age children is in less than half of the countries a 
regular part of health screening programmes in children. 
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Referral 
Neonates who do not pass the test are in most countries referred to a combined audiology / 
ear, nose, throat (ENT) institution, in some countries to an audiologist and in a few countries 
to an ENT specialist. 
 
Funding 
In most countries the government or health insurance finances the neonatal hearing screening 
programme. Other reported funding includes hospital, parents and private funds. 
 
Coverage 
Universal NHS programmes have a coverage of an estimated 10-50% in Romania, 50-95% in 
nine countries, and more than 95% in 23 other countries. Malta has a nation-wide selective 
screening programme with a good coverage, whereas Bulgaria, Moldova and Serbia have 
local selective screening programmes, with a low coverage. Albania had for a few years a 
pilot nation-wide universal screening programme with a low coverage. 
 
Data is presented in more detail in table 3 and Map 2. 
 
 
Table 3. Overview of neonatal hearing screening programmes in 38 European countries. 
Scope =  scope of hearing screening programme (nat =   nation-wide, loc =  local, past =  pilot 
from 2004-2008), Strat = screening strategy (all =  all neonates, select =  only neonates at risk 
e.g. prematures), Test = test used for well babies in the programme (first test when staged)( 
test a or test b =  both tests are used in the programme, test a +  test b =  both tests are used in 
one neonate), St = stages (number of tests before referral), last test =  test before referral if 
staged, ears = ears tested (both or only the first ear with a pass), test risk group = test used in 
neonates at risk (first test when staged), refer = referred to ENT, audiological institution or a 
combination (both), funding = (insur =  health insurance, hosp =  hospital, par =  parents, 
NGO = non-government organization, int. project =  international project), Cov =   coverage  
(infants screened / infants meant to be screened x 100), child: standard hearing test in 
screening programme at child age. 
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Country Scope Strat Test St Last test Ears Test risk group Refer Funding 
Cov 
(%) 
 Child 
Albania past all OAE 3 full ABR 2 OAE ENT private <10  - 
Austria nat all OAE 3 aABR 2 OAE audio state >95  - 
Belgium (Fl) nat all aABR+ ASSR 2 aABR 2 
aABR + 
ASSR audio state >95 
 
 
Belgium 
(W) nat all OAE 2 full ABR 2 full ABR both par, state 90 
 
- 
Bulgaria loc select OAE 2 aABR 2 aABR both private, hosp 25 
 
 
Croatia nat all OAE 3 aABR 2 aABR both insur >95  - 
Cyprus nat all OAE 3 aABR 2 aABR audio NGO >95  + 
Czech rep nat all OAE 1  2 OAE ENT insur >50   
Denmark nat all OAE or 
aABR 2 aABR 2 OAE+aABR audio state >95 
 
+ 
Estonia nat all OAE or 
aABR 3 aABR 2 OAE both insur >95 
 
+ 
Finland nat all OAE 2 OAE 1/2 aABR both state >95  + 
France nat all OAE or 
aABR 3 
aABR or 
full ABR 2 aABR both state >50 
 
+ 
Germany nat all OAE or 
aABR 2 aABR 2 aABR both insur >95 
 
+ 
Greece nat all OAE 1  2 aABR both par >50  + 
Hungary nat all OAE 2 OAE 2 aABR both insur, state >50  + 
Iceland nat all OAE 3 aABR 2 OAE both state >50  - 
Ireland nat all OAE 2 aABR 2 OAE+aABR audio state >95  - 
Israel nat all OAE 3 aABR 2 OAE+aABR audio state >95  + 
Italy nat all OAE 3 aABR 2 OAE+aABR both hosp 70   
Latvia nat all OAE 3 ABR 2 aABR and/or 
other both state >95 
 
+ 
Lithuania nat all OAE 3 aABR 2 OAE+aABR both insur 50-90 
 
- 
Luxembourg nat all OAE 2 OAE 2 aABR ENT state >95  + 
Malta nat select OAE 1  2 aABR both state >95   
Moldova loc select OAE 2 aABR 2 OAE both int. project >50  - 
Montenegro nat all OAE 4 aABR 2 aABR both state >95  - 
Netherlands nat all OAE 3 aABR 2 aABR audio state >95  + 
Norway nat all OAE 3 aABR or full ABR 2 aABR both state >95 
 
 
Poland nat all OAE 2 OAE 2 OAE both insur >95  - 
Portugal nat all OAE 3 aABR 2 aABR both hosp >95  - 
Romania nat all OAE 2 aABR 2 OAE+aABR both state >10  - 
Serbia loc select OAE 1  2 OAE both hosp 25  + 
Slovenia nat all OAE 3 aABR 2 aABR both insur >95  - 
Slovakia nat all OAE 2 OAE 2 aABR both insur, state >95   
Spain nat all OAE or OAE+aABR 3 aABR 2 
aABR or 
OAE+aABR audio state >95 
 
- 
Sweden nat all OAE or 
aABR 3 
aABR or 
full ABR 2 
OAE+aABR 
or aABR both state >95 
 
+ 
Switzerland nat all OAE 1  1/2 OAE or 
aABR both hosp >95 
 
+ 
Turkey nat all OAE 3 aABR 2 aABR both state 90   
UK nat all OAE 3 aABR 2 aABR audio state >95  + 
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Public-health  
Extra information on public-health screening programmes was obtained from 23 countries 
including one region in Belgium (Flanders).  
All 23 countries have a public health screening programme in place, but in Albania, Belgium 
and Spain this is a regional programme. In the Netherlands and Sweden there is a combination 
of national and regional programmes in place. Almost all countries have a programme for all 
children, except for Albania where there is only selective screening available. Screening is not 
free of charge in Albania, Bulgaria and Czech Republic and is obligatory in Bulgaria, 
Flanders, Greece, Hungary and Turkey.  
 
Tests 
Weight, height and head circumference are measured  in all countries, cardiac function in all 
but Albania, lung function in all but Albania and Flanders, vision in all but Albania and 
Turkey, hearing in all but Albania and Malta, motor skills in all but Czech Republic and the 
UK, speech and language development in all but Albania, Bulgaria, Czech Republic and the 
UK, cognitive development in all but Albania, Czech Republic, Flanders and the UK and 
psychosocial development is screened in all countries but Albania, Bulgaria, Czech Republic, 
Flanders, Germany, Israel, Sweden and the UK.  
 
Referral, funding and coverage 
Referral is most often to a specialist. Funding is provided mostly by the government or health 
insurance. Coverage is above 80% in all countries, except Albania.  
 
Data is presented in more detail in table 4 and Map 3. 
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Table 4. Public health screening programmes in 23 European countries. Scope =  public-
health screening programme (nat =  nation-wide, loc =  local), All = screening programme for 
all children, WHH =  weight, height and head circumference, Cog =  cognitive development, 
Psycho = psychosocial aspects, Funding (insur =  Health Insurance, par =  parents, munic = 
Municipalities) Cov =  Coverage)  
 
Country Scope All Vision Hearing WHH Heart Lung Motor Speech Cog Psycho Funding Cov (%) 
Albania loc - - - + - - + - - - state, par >10 
Belgium (Fl) nat + + + + + - + + - - state >95 
Bulgaria nat + + + + + + + - + - state, insur >95 
Croatia nat + + + + + + + + + + insur >95 
Czech rep nat + + + + + + - - - - insur >80 
Finland nat + + + + + + + + + + state, munic >95 
France nat + + + + + + + + + + state >95 
Germany nat + + + + + + + + + - insur >80 
Greece nat + + + + + + + + + + state, par   
Hungary nat + + + + + + + + +   state >95 
Iceland nat + + + + + + + + + + state >95 
Israel nat + + + + + + + + + - state >95 
Macedonia nat + + + + + + + + + + state, insur >95 
Malta nat + + - + + + + + + + state >95 
Montenegro nat + + + + + + + + + + insur >95 
Netherlands nat + + + + + + + + + + state, munic >95 
Portugal nat + + + + + + + + + + state >95 
Serbia nat + + + + + + + + + + insur >80 
Slovenia nat + + + + + + + + + + insur >95 
Spain loc + + + + + + + + + + state >95 
Sweden nat + + + + + + + + + -   >95 
Turkey nat + - + + + + + + + + state >95 
UK nat + + + + + + - - - - state 
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Questionnaire answer check 
Several changes were made based on the first round of questionnaire answers. The following 
changes in hearing screening data were made: for Belgium (Flanders) the ASSR was added as 
test for neonates at risk. For Finland ³testing one ear´ was changed to ³testing one ear or both 
ears´. For France ³testing one ear and testing both ears´ was changed to ³always testing both 
ears´. For Italy coverage of ³> 95%´ was changed to ³70%´. For Malta selective screening, 
and not population-wide screening, was confirmed. For Poland ³non-staged screening´ was 
changed in ³staged screening´. For Israel, Italy, Lithuania and Switzerland ³RQO\aABR 
testing´ for neonates at risk was corrected to ³OAE and/or aABR´. 
Vision screening data was revised: for Austria funding was changed from ³health insurance´ 
to ³health insurance and state´. For Belgium (Flanders) personnel was changed from ³nurse´ 
to ³nurse and youth health care physician´, testing of stereopsis and colour vision was added 
and VA chart was changed from ³Landolt C´ to ³Pictures and HOTV´. For Croatia VA chart 
was changed from ³only Tumbling E´ to ³Pictures, Lea and Tubling E´. For Czech Republic 
Pictures and Lea chart were added. For Denmark the ³Snellen chart´ was changed to 
³Pictures´ and coverage was changed from ³>80%´ to ³>95%´. For Iceland Snellen chart was 
added. For Israel coverage was changed from ³>95%´ to ³>80%´. For Italy funding was 
changed from ³state´ to ³regions´. For Latvia ³Picture chart and Tumbling E´ was corrected 
to ³Cardiff, Pictures, Tumbling E and numbers´. For Norway the Sheridan Gardiner chart was 
added. For Slovenia autorefraction was corrected as in Slovenia autorefraction is only 
performed in ophthalmology clinics for referred children and not for screening. For Sweden 
the Konstantin Moutakis chart was added. For the UK funding was corrected from ³state´ to 
³regions´ and personnel were changed from ³orthoptist, optician and optometrist´ to 
³orthoptist, nurse and practice assistant´.  
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DISCUSSION 
This study assessed population-based vision and hearing screening programmes in all EU 
countries. We showed that large differences exist in paediatric population-based vision and 
hearing screening programmes throughout the EU. Large differences were found in tests used, 
age and frequency of testing. First measurement of VA varies from three to seven years of 
age, but in most countries it is measured before the age of five. In children age three and four 
picture charts, including Lea Hyvarinen are used most, in children over four Tumbling E and 
Snellen. Vision screening is performed mostly by paediatricians, ophthalmologists or nurses. 
As first hearing screening test, otoacoustic emission (OAE) is used most in healthy neonates 
and auditory brainstem response (ABR) in premature newborns. The majority of hearing 
testing programmes are staged. Children are referred after one, two, three or four abnormal 
tests.  Funding is by health insurance, state, regions, municipalities, charity, hospital, parents 
or private funding. A high coverage is reached in most countries for both vision and hearing 
screening.  
 
Our study was limited by the difficulty in obtaining referenced or first-hand data sources from 
respondents. We have where possible tried to maintain the quality of our data by involving 
clinicians who were involved in population based screening, and cross-checking their answers 
with the answers given by the general screening professionals. It was most difficult to get 
accurate information on funding and coverage, while information on tests, personnel and age 
was easier to obtain. The percentage of coverage may have been overestimated by the country 
representatives 
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Screening of vision and hearing deficits has similarities, but also differences. An essential 
difference between vision and hearing screening is that objective tests are available for 
hearing screening at a very early age, enabling screening directly after birth. This probably is 
the reason for the more uniform approach and higher coverage that was reported for hearing 
screening as compared to vision screening. As we assumed that the personnel operating the 
screening apparatus at the hospital or during home visits would be a technician, we did not 
ask the profession explicitly. There are only two tests for hearing screening available; OAE 
and aABR. The major difference in hearing screening is primarily the number of screening 
stages before referral. Multiple stage screening is more expensive, but results in a larger 
specificity, which reduces the number of false referrals to specialized and expensive 
audiological care centres.23,26 Two or three stages of screening before referral is most 
frequently used, with mostly OAE as first test and aABR as last test. Boshuizen et al. 
calculated that three stages is preferable in terms of cost-effectiveness, but this is not based on 
combined use of OAE and aABR.26 A hearing test in pre-school or early school-age children 
has the potential to discover hearing loss acquired during the years after birth, which occurs 
more rarely. These tests have been abolished in many countries in Europe. 
In our opinion the large diversity in screening programmes may have resulted from the fact 
that these programmes arose piecemeal prior to the reporting of any robust evidence on 
effectiveness and cost-effectiveness to guide protocol design or implementation. Another 
reason could be that in addition most of the preventive health care programmes are 
government funded and, therefore, competition is lower than in curative health-care. Careful 
assessment is needed of the influence of the kind of funding (e.g. state, health insurance or 
municipalities) on the efficiency of screening.  
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The large differences found in population-wide vision and hearing screening in children in all 
EU countries necessitate further study on the relative costs and effectiveness of the different 
approaches to screening. For instance 12 different VA charts are used, 10 professions are 
involved in vision screening, one to four hearing screening tests take place before referral and 
eight funding sources are involved. The large number of screening tests used in vision 
screening should be compared. Efficiency of screening (i.e. sensitivity and specificity per 
euro) should be calculated for screening performed by different screening professions.  
 
We plan to extend the questionnaire and include data sources in a much larger and more 
detailed questionnaire. 7KH(86¼5((1VWXG\JURXSDQ(8-wide consortium (appendix), is 
currently preparing a Europe-wide study to  compare and optimise the cost-effectiveness of 
vision and hearing screening and give country-specific advice in all candidate, associate and 
full EU-member states.  
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APPENDIX A  
EUS¼REEN consortium: EU vision: 
Austria: Langmann A; Lindner S; Gaugl H (Medical University Graz), Belgium Flanders: ten 
Tusscher M (University Clinic Brussel), Guérin C; Hoppenbrouwers K, van Lammeren M ( 
University Leuven), Boelaert K (Kind en gezin, Brussel), Godts D (University Hospital 
Antwerp), Belgium Wallonia: Paris V (CHU de Liège), Bauwens A (Bastogne), Bulgaria: 
Stateva D (Medical University Pleven), Croatia: Petrinovic-Doresic J; Bjelos M (University 
Eye Clinic University Hospital "Sveti Duh", Zagreb), Novak-Stroligo M (Clinical Hospital 
Rijeka), Alpeza-Dunato Z (Rijeka University Hospital Center), Cyprus: Gavrielides 
Michaeloudes M, Czech Republic: Dostálek M (Center of Paediatric Ophthalmology, 
BINOCULAR s.r.o. Litomysl & Masaryk's University, Brno), Zobanova A (Prague), 
Jerabkova A, Denmark: Hesgaard H, Welinder LG (Aalborg University Hospital), Sandfeld L 
(University of Copenhagen, Roskilde Hospital), Larsen S (Squinting Eyes, Copenhagen), 
Estonia: Levin M (Ida-Tallinn Central Hospital), Klett A; Somma K (Tallinn), Ismagilova S, 
Finland: Hyvärinen L (Developmental Neuropsychology, University of Helsinki), France: 
Thouvenin D (Purpan University Hospital, Toulouse), Coursager K, Germany: Elflein H; Pitz 
S (University Hospital, Johannes Gutenberg-University, Mainz), Lenk-Schaefer M 
(Nürnberg), Van-Waveren M (Tübingen), Greece: Ziakas NG (Aristotle University 
Thessaloniki), Polychroniadis Scouros S (Hygeia Hospital Athens), Hungary: Knezy K; 
Nemeth J (Semmelweis University, Budapest), 6RSURQL$$QQD6RSURQL¶V3ULYDWH(\H&OLQLF
Budapest),  Facskó A; Berkes S (University of Szeged), Iceland: Gudmundsdottir E 
(Landspitalinn, University of Iceland, Reykjavik), Ireland: McCreery K (Blackrock Clinic, 
Dublin), Israel: Morad Y (Assaf Harofeh Medical Center, Tel Aviv University, Zrifin), Ancri 
O (Goldschleger Eye Institute, Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv 
University), Italy: Nucci P; Serafino M; Lembo A (University Hospital San Giuseppe, Milan), 
Bottin D (Hospital of Bolzano), Latvia: Valeina S (Riga Children's University Hospital), 
Lithuania: Misevice A (Clinic of Ophthalmology, Kaunas University of Medicine), Asoklis 
RS (ENT and Eye Clinic, Vilnius, Lithuania), Luxembourg: Planata-Bogdan B (Service 
Orthoptique et Pléoptique, Esch-sur-Alzette), Malta: Francalanza M (Mater Dei Hospital, 
Malta) MJ Gouder, Montenegro: Jovovic N; Pojuzina N (Children's Hospital, Podgorica), 
Netherlands: Sjoerdsma T (Municipal Health Service, Amsterdam), van Rijn R (VU 
University Medical Center, Amsterdam), Norway: Osnes-Ringen O, Moe M (Center for Eye 
Research, Oslo University Hospital), Poland: Bakunowicz-Lazarczyk A (Medical University 
of Bialystok), Portugal: Reich-d'Almeida F (Faculty of Medical Sciences New University 
Lisbon), Marques Neves C (Centro Hospitalar de Lisboa Norte, Lisbon), Reich d' Almeida I, 
Oliveira M, Romania: Vladutiu C &OLQLFD2IWDOPRORJLFă&OXM-Napoca), Serbia: Stankovic B; 
'MRNLü9 (University of Belgrade Clinical Center of Serbia), Slovakia: Gerinec A (Klinika 
Detskej Oftalmológie DFNsP-LF UK, Bratislava), Slovenia: Stirn Kranjc B (University 
Medical Centre, Ljubljana), Spain: Gomez-de-Liano Sanchez R (Hospital Clínico San 
Carlos, Madrid), Rajmil L; Prats B (Catalan Agency for Health Quality and Assessment), 
Sweden: Nilsson J (Institute of Neuroscience and Physiology, The Sahlgrenska Academy, 
University Gothenburg), Flodin S (The Sahlgrenska Academy, University Gothenburg), 
Switzerland: Landau K (University of Zurich), Sturm V (Kantonhospital St. Gallen), Zuber C 
(Cabinet orthoptie Neuchâtel et La Chaux-de-Fonds), Glauser V, Turkey: Atilla H (Ankara 
University), UK: Horwood AM (University of Reading), Williams C (University of Bristol), 
Shea S (Orthoptic Department, North West Wales NHS Trust, Ysbyty Gwynedd, Bangor), 
Griffiths H; J Carlton (University of Sheffield). 
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(86¼5((1FRQVRUWLXP(8KHDULQJ 
Albania: Birkena Qirjazi, (University of Medicine of Tirana), Austria: Markus Gugatschka, 
(Medical university Graz), Belgium Flanders: Luc Stappaerts (Kind en Gezin, Brussels), 
Belgium Wallonia: Bénédicte Vos (Centre d'Epidémiologie Périnatale-School of Public 
Health/Université libre de Bruxelles, Brussels), Bulgaria: Mario Milkov (St. Petka Eye and 
Ear Clinic, Varna), Croatia: Marko Velepic (Rijeka University Hospital Center, Rijeka), 
Cyprus: Chryssoula Thodi (European University Cyprus, UNHS Programmeme), Czech Rep: 
Josef Syka (Czech Academy of Science, Prague), Denmark: Therese Ovesen (Aarhus 
University Hospital), Estonia: Liina Luht (East Tallinn Central Hospital), Finland: Riina 
Niemensivu; Antii Aarnisalo (Helsinki University Hospital), France: Françoise Denoyelle 
(Hopital Necker-Enfants Malades, Paris), Germany: Annerose Keilmann (Johannes 
Gutenberg-Universität Mainz), Katrin Neumann (Ruhr-University Bochum),  Greece: Thomas 
Nikolopoulos (Athens University School of Medicine), Hungary: Zsolt Beke (Sanct Rokus 
Hospital, Baja), Iceland: Ingibjörg Hinriksdóttir (National Hearing and Speech Institute of 
Iceland, Sími), Ireland: Ann O'Connor (RCSI Surgery, Dublin),Israel: Lisa Rubin (Public 
Health Service, Ministry of Health, Jerusalem), Italy: Patrizia Trevisi; Alessandro Martini 
(University of Padova), Ferdinando Grandori, (Institute of Biomedical Engineering, Milan), 
Latvia: 6DQGUD.XãƷH (Latvia Children Hearing center), Lithuania: Eugenijus Lesinskas 
(University Hospital Santariskiu Clinics, Vilnius), Luxembourg: Jean Marc Hild (Services 
Audiophonologiques, Strassen), Malta: Anthony Fenech, (Mater Dei Hospital, Msida), 
Moldova: Anghelina Chiaburu (Republican Center of Audiology, Chisinau), Montenegro: 
Ognjen Jovicevic, (Institute for Children's disease, Clinical Center of Montenegro, 
Podgorica),  Norway: Karl Nordfalk; Sverre Medbø (Universitetssykehus, Oslo), Poland: 
Witold 6]\IWHU*UDĪ\QD*UHF]ND(8QLYHUVLW\RI0HGLFDO6FLHQFHV3R]QDĔ), Portugal: Luisa 
Monteiro (Lisbon), Romania: Madalina Georgescu, (University of Medicine and Pharmacy, 
Bucharest),Serbia: Snezana Andric Filipovic (Clinical Center of Serbia, Clinic of ENT and 
Maxillofacial Surgery, Belgrade), Slovakia: Gabriela Pavlovcinova, Milan Profant 
(University Hospital Bratislava), Slovenia: Saba Battelino; Irena Hocevar Boletezar 
(University Medical Center, Ljubljana), Spain: Faustino Núñez-Batalla (Hospital 
Universitario Central de Asturias), Oviedo Javier Cervera (Hospital Infantil Universitario 
Niño Jesús, Madrid), Sweden: Inger Uhlén,  (Karolinska University Hospital, Stockholm), 
Switzerland: Dorothe Veraguth, (University Hospital Zürich), Turkey: Huban Atilla 
(University Ankara), UK: Gwen Carr; Adrian Davis; Adam Bruderer (UCL Ear Institute, 
London), Tony Sirimanna, (Great Ormond Street Hospital for Children, London) 
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(86¼5((1FRQVRUWLXP(8Public health: 
Albania: Qirjazi B (Faculty of Medicine, Science Medical University of Tirana), Belgium 
Flanders: Hoppenbrouwers K; Guérin C (KU University Leuven), Bulgaria: Georgieva L 
(Faculty of Public Health, Medical University, Sofia), Croatia: Rukavina T (University Rijeka 
School Medicine), Czech Republic: Bourek A (Masaryk University), Finland: Hietanen-
Peltola M (The National Institute of Health and Welfare), France: Jégat C (Association 
Nationale pour l'Amélioration de la Vue Paris), Germany: Ottová-Jordan V(University 
Medical Center Hamburg-Eppendorf), Greece: Polychroniadis Scouros S (Hygeia Hospital 
Athens), Hungary: Kovacs A (Scientific Committee at Association of Primary Care 
Paediatricians), Iceland: Jónsdóttir LS (Directorate of Health), Israel: Morad Y (Department 
of Ophthalmology, Assaf Harofeh Medical Center, Tel Aviv University, Zrifin); Grotto I 
(Israel Ministry of Health), Malta: Farrugia Sant'Angelo V (Ministry for Health, Floriana, 
Malta), Macedonia: Memeti S (Institute of Public Health of the Republic of Macedonia), 
Montenegro: Mugosa B, (Institute of Public Health of Montenegro, Podgorica), Netherlands: 
Raat H (Department of Public Health, Erasmus Medical Center Rotterdam), Portugal: Gaspar 
T (Institute of Psychology and Educational Sciences, Lusiada University, Lisbon), Serbia: 
Zivkovic Sulovic M (Institute of public health of Serbia), Slovenia: Juricic M (University of 
Ljubljana, Medical Faculty), Spain: Rajmil L (Catalan Agency for Health Quality and 
Assessment), Sweden: Hjern A, (Karolinska Institutet), Turkey: Atilla H (Ankara University), 
UK: Dahlmann-Noor A (NIHR Biomedical Research Centre at Moorfields Eye Hospital and 
UCL Institute of Ophthalmology) 
 
The authors thank Ferdinando Grandori, Gwen Carr, Anneke Meuwese-Jongejeugd, Bert van 
Zanten, Cécile Guérin, Karel Hoppenbrouwers for their information, comments and 
corrections. The authors had no commercial or propriety interest. 
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APPENDIX B 
 
Glossary: 
 
aABR: automated Auditory Brainstem Response; detects responses in the brainstem after offering 
clicks of 35 or 40 dB via headphones. 
Amblyopia (lazy eye):  reduced vision, usually in one eye caused by abnormal visual experience in 
early childhood e.g. strabismus and refractive error.  
Bruckner test: A direct ophthalmoscope is used in a darkened room and the red reflex in both eyes is 
assessed simultaneously at 0.6 to 0.9 metres. The colour and brightness of the red reflexes are 
compared. The colour is often more orange than red. The test is easy and quick to perform and can 
reliably detect media opacities. Strabismus and refractive error can also be detected, but with a lower 
sensitivity. Refractive error can give a yellow-white edge to a red reflex. 
Hirschberg test: corneal light reflex test. The corneal light reflex test is performed to assess 
ocular alignment. The test is performed by shining a light into the child eyes from a distance 
and observing the reflections on the cornea with respect to the pupil. The location of the light 
reflexes should be symmetric. 
OAE: Otoacoustic emissions; sounds produced by inner ear hair cells if the hearing threshold is better 
than 35 dB and picked up by a microphone in the ear canal. 
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DATA SUPPLEMENT 
 
Q1 
 
in your country is there a: 
Public-health 
screening 
programme?  None Regional National 
Employer-
based Other           
Eye screening 
programme?  None Regional National 
Employer-
based Other            
Who pays for 
eye screening?  Parents 
Health 
Insurance Councils 
Provinces-
Regions State 
Parents 
employ
er Companies 
 
Charity Other 
Who does the 
eye screening?  
Ophthalmo
logist Orthoptist 
Paediatric
ian 
Youth 
health care 
physician Nurse 
Ophth 
practice 
assistan
t Optometrist 
Opticia
n 
School 
physician Other:  
Coverage 
among eligible 
children?  >95% >90% >80% >60% >40% >20% >10% <10% 
Just 
starting Other:  
Parents' 
secondary 
benefits:  
Eye exam 
is free 
Eye exam 
is cheap 
Financial 
reward 
During 
working 
hours 
Conditio
n for 
school 
entry 
Free 
glasses Obligatory     Other:  
Infant eye-
screening 
tests?  Inspection Fixation 
Red 
fundus 
reflex Hirschberg Brückner 
Cover 
test 
Pupillary 
reflexes 
Motilit
y   Other:  
At approx 1 week 2 weeks 3 weeks 1 month 6 weeks 
2 
months 10 weeks 
3 
months 4 months Other:  
Preverbal eye-
screening 
tests?  Inspection Fixation 
Red 
fundus 
reflex Brückner 
Pupillary 
reflexes 
Motilit
y Hirschberg 
Cover 
test   Other:  
at approx  6 months 9 months 1 year 15 months 
18 
months 
21 
months 2 years 
27 
months 
30 
months Other:  
Autorefraction
photoscreenin
g at:  6 months 9 months 1 year 15 months 
18 
months 
21 
months 2 years 
27 
months 
30 
months Other:  
Preschool eye 
screening?  Inspection Fixation 
Red 
fundus 
reflex Brückner 
Pupillary 
reflexes 
Motilit
y Hirschberg 
Cover 
test   Other:  
visual acuity 
measured 
with:  
Picture 
chart 
Lea 
Hyvarinen HOTV 
Tumbling 
E 
Landolt 
C Snellen Also:  
Stereop
sis 
Color 
vision Other:  
at approx 3 years 3,5 years 4 years 4,5 years 5 years 
5,5 
years 6 years 
6,5 
years 7 years Other:  
Positively 
screened 
children 
referred to:  
General 
practitioner 
Ophthalmo
logist 
Orthoptis
t Optician 
Optometr
ist         Other:  
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In your country is there a:  
Public-health screening 
programme for children?  
no regional national other 
Neonatal hearing screening 
programme (NHS) 
no regional national other 
In what year approximately did 
the programme start? 
   
  
How is the NHS programme 
financed? 
parents hospital government health 
insurance 
What % of neonates are actually 
screened? 
>95% >50% >10% <10% 
Which test is used for NHS? OAE aABR other 
Different test for neonates at risk, 
f.e. prematures? 
no  aABR other 
Are both ears tested? one ear both ears     
Is NHS staged? no OAE-
aABR 
OAE-OAE-
aABR 
other 
Is NHS in your country universal? selective?   
What is the follow up if a neonate 
tests positive on NHS?  
audiologic 
examination 
ENT combination other 
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In your country is 
there a:                     
Public-health 
screening programme 
for children?  no national regional             other 
In what year did the 
programme start?                     
General or selective 
screening 
no 
screening general selective   
risk 
groups           
Who pays for the 
screening programme? parents charity hospital 
govern
ment 
health 
insurance         other 
Parents' secondary 
benefits:  
exam is 
free of 
charge 
exam is 
cheap 
financial 
reward 
during 
workin
g hours obligatory         other 
Coverage among 
eligible children?  >95% >80% >50% >10% <10%           
At what age is 
screening performed?                     
Are the following tests 
performed 
weight, 
height, 
head 
circumfere
nce heart lung vision hearing 
motor 
skills 
speech 
and 
language 
cognitive 
develop
ment 
Psycho 
social 
aspects other 
Who performs the 
screening? doctors paramedic nurses 
screeni
ng 
physici
an 
school 
physician         other 
Positively screened 
children are referred 
to:  GP hospital  specialist 
private 
clinics           other 
